Stockscreener 앱 받기
116.65
1.36%
1.56
시간 외 거래:
116.00
-0.65
-0.56%
전일 마감가:
$115.09
열려 있는:
$115.01
하루 거래량:
1.36M
Relative Volume:
0.81
시가총액:
$23.30B
수익:
$5.36B
순이익/손실:
$1.43B
주가수익비율:
16.50
EPS:
7.0718
순현금흐름:
$1.42B
1주 성능:
-1.58%
1개월 성능:
+16.94%
6개월 성능:
+9.83%
1년 성능:
+68.50%
1일 변동 폭
$114.13
$117.18
1주일 범위
$110.56
$118.93
52주 변동 폭
$67.17
$118.97
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
116.65 | 22.99B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 121.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 69.66B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.99B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 39.21B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.27B | 4.29B | 577.22M | 641.34M | 4.2086 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-02-05 | 개시 | H.C. Wainwright | Buy |
| 2026-01-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Incyte CMO Steven Stein sells $3.19m in company stock - Investing.com
Lobbying Update: $110,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Form 4 Incyte Corporation For: 16 July By Investing.com - Investing.com Canada
Incyte (INCY) R&D chief withholds 22,919 shares to cover taxes - Stock Titan
Incyte Corp (NASDAQ: INCY) EVP reports 1,949-share RSU tax withholding - Stock Titan
Incyte Corp (NASDAQ: INCY) PAO reports 1,790 shares withheld for RSU taxes - Stock Titan
What to Expect From Incyte's Q2 2026 Earnings Report - Barchart.com
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Citizens maintains Incyte stock rating on pipeline progress - Investing.com
INCY Maintains Overweight Rating -- Price Target Raised to $134 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on VWD drug data - Investing.com
H.C. Wainwright reiterates Incyte stock rating on VWD drug data By Investing.com - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (INCY) Reveals Promising Data for New Treatment in Von Wi - GuruFocus
Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3 - Yahoo Finance
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types - BioBuzz
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis - Yahoo Finance
INCY Maintained by BMO Capital -- Price Target Raised to $112 - GuruFocus
BMO raises Incyte stock price target to $112 on Opzelura strength - Investing.com Australia
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disord - Benzinga
BMO raises Incyte stock price target to $112 on Opzelura strength By Investing.com - Investing.com India
Incyte reports 81% bleeding reduction in VWD study - grafa.com
Incyte reports phase 1/2 trial results for bleeding disorder drug By Investing.com - Investing.com South Africa
Incyte reports phase 1/2 trial results for bleeding disorder drug - Investing.com
Incyte stock holds steady as pipeline progress supports long-term growth outlook - Ad-hoc-news.de
Funds slated to go to Incyte will bankroll corridor improvement program - Delaware Business Now
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Forte, First Tracks soar on CD122 success in vitiligo; celiac next - BioWorld News
Incyte stock steadies on its oncology franchise - ad-hoc-news.de
2 Fast-Growing Pharmaceutical Stocks to Buy Now - Yahoo Finance
Incyte (INCY) Set to Release Q2 2026 Earnings with Positive Mark - GuruFocus
Incyte stock hits 52-week high at 118.77 USD - Investing.com
Incyte stock hits 52-week high at 118.77 USD By Investing.com - Investing.com UK
Incyte to Report Second Quarter 2026 Financial Results - BioSpace
Incyte to Report Second Quarter Financial Results - Business Wire
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Form 4 Incyte Corporation For: 7 July By Investing.com - Investing.com Canada
INCYTE (INCY) CEO’s RSU tax withholding adjusts reported share holdings - Stock Titan
INCYTE (INCY) CMO has 2,177 shares withheld to cover equity award taxes - Stock Titan
INCY Maintained by RBC Capital -- Price Target Raised to $99.00 - GuruFocus
Incyte Corporation (INCY) Completes Acquisition of Vega Therapeu - GuruFocus
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (INCY) Completes Acquisition of Vega Therapeutics - GuruFocus
Incyte completes $1.25B acquisition of Vega Therapeutics - grafa.com
Incyte completes $1.25B Vega Therapeutics acquisition By Investing.com - Investing.com South Africa
Incyte completes $1.25B Vega Therapeutics acquisition - Investing.com
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio - Business Wire
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Truist Financial Maintains Incyte(INCY.US) With Hold Rating - Moomoo
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.75%
3.94%
자본화:
|
볼륨(24시간):